Oliver Schacht Ph.D.
Net Worth

Last updated:

What is Oliver Schacht Ph.D. net worth?

The estimated net worth of Dr. Oliver Schacht Ph.D. is at least $2,404,480 as of 31 Mar 2023. He owns shares worth $141,000 as insider and has received compensation worth at least $2,263,480 in OpGen, Inc..

What is the salary of Oliver Schacht Ph.D.?

Dr. Oliver Schacht Ph.D. salary is $565,870 per year as Chief Executive Officer, Pres & Director in OpGen, Inc..

How old is Oliver Schacht Ph.D.?

Dr. Oliver Schacht Ph.D. is 54 years old, born in 1971.

What stocks does Oliver Schacht Ph.D. currently own?

As insider, Dr. Oliver Schacht Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
OpGen, Inc. (OPGN) Chief Executive Officer, Pres & Director 30,000 $4.7 $141,000

What does OpGen, Inc. do?

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Oliver Schacht Ph.D. insider trading

OpGen, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 12,469 N/A N/A
Option
Common Stock 12,469 N/A N/A
Option
Common Stock 1,938 N/A N/A
Option
Restricted Stock Units 1,938 N/A N/A
Option
Restricted Stock Units 1,875 N/A N/A
Option
Common Stock 1,875 N/A N/A
Option
Restricted Stock Units 38,750 N/A N/A
Option
Common Stock 38,750 N/A N/A
Purchase
Common Stock 10,000 $1.5 $14,960
Purchase
Common Stock 5,000 $3.08 $15,400
Purchase
Common Stock 20,000 $2.24 $44,700

OpGen key executives

OpGen, Inc. executives and other stock owners filed with the SEC: